A61K 40/4204
Epidermal growth factor receptors [egfr]
Official title: {Epidermal growth factor receptors [EGFR]}
A61K40/4204 (Epidermal growth factor receptors [egfr]) appears on 153 US grants and 441 published applications in this corpus.
Search patents in A61K- Granted patents
- 153
- Published applications
- 441
- Assignees
- 191
- Inventors
- 807
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 6 |
| 2015 | 1 | 5 |
| 2016 | 6 | 5 |
| 2017 | 3 | 17 |
| 2018 | 1 | 16 |
| 2019 | 6 | 23 |
| 2020 | 5 | 47 |
| 2021 | 13 | 56 |
| 2022 | 13 | 55 |
| 2023 | 27 | 47 |
| 2024 | 30 | 75 |
| 2025 | 27 | 45 |
| 2026 | 20 | 39 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Method for high level and stable gene transfer in lymphocytes1 Sep 2026US 12,723,265 B2Julius-Maximilians-UniversitäT WüRzburg
- Compositions and methods for treating cancer with anti-CD33 immunotherapy25 Aug 2026US 12,714,750 B2Lentigen Technology, Inc.
- Synthetic pathway activators14 Jul 2026US 12,679,881 B2Arsenal Biosciences, Inc.
- Small Molecule Based Method Of Modifying T Cells8 Oct 2026US 2026/0308520 A1Agency for Science, Technology and Research
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Coreceptor chimeric antigen receptor24 Sep 2026US 2026/0284111 A1
Most cited
By later US patents
- Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor113US 9,394,368 B2Novartis AG · 2016
- Compositions, methods, and computer systems related to making and administering modified T cells107US 9,499,855 B2Elwha LLC · 2016
- Bispecific chimeric antigen receptors and encoding polynucleotides thereof92US 9,447,194 B2Seattle Children's Hospital · 2016
- Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer87US 9,233,125 B2University of Maryland, Baltimore · 2016
- Bispecific chimeric antigen receptors and methods of use thereof to treat cancer26US 10,189,903 B2Seattle Children's Hospital · 2019